DPP4 and chronic myelogenous leukemia, BCR-ABL1 positive: A Wilcoxon signed-rank test showed that a six-month treatment with imatinib elicited a statistically significant change in the number and percentage of CD26 LSC in patients with CML (absolute count, Z = -4.2, p ≤ 0.001 and percentage CD26, Z = -2.5, p = 0.011).